MERUS N V's ticker is MRUS and the CUSIP is N5749R100. A total of 1 filers reported holding MERUS N V in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,201,287 | +28.7% | 93,354 | +43.7% | 0.00% | +100.0% |
| Q2 2023 | $1,710,239 | +43.1% | 64,954 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,195,154 | +7.4% | 64,954 | -9.7% | 0.00% | 0.0% |
| Q4 2022 | $1,113,128 | -17.2% | 71,954 | +7.1% | 0.00% | 0.0% |
| Q3 2022 | $1,345,000 | -9.5% | 67,154 | +2.3% | 0.00% | 0.0% |
| Q2 2022 | $1,486,000 | -14.4% | 65,654 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $1,736,000 | -10.6% | 65,654 | +7.5% | 0.00% | 0.0% |
| Q4 2021 | $1,942,000 | +87.3% | 61,054 | +29.5% | 0.00% | 0.0% |
| Q3 2021 | $1,037,000 | +4.3% | 47,154 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $994,000 | -5.7% | 47,154 | -6.5% | 0.00% | 0.0% |
| Q1 2021 | $1,054,000 | +66.2% | 50,454 | +39.6% | 0.00% | – |
| Q4 2020 | $634,000 | +46.1% | 36,154 | 0.0% | 0.00% | – |
| Q3 2020 | $434,000 | -25.4% | 36,154 | 0.0% | 0.00% | – |
| Q2 2020 | $582,000 | – | 36,154 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,600,000 | $32,048,000 | 13.34% |
| Lynx1 Capital Management LP | 613,071 | $12,280,000 | 11.08% |
| Aquilo Capital Management, LLC | 1,507,109 | $30,187,000 | 10.88% |
| COMMODORE CAPITAL LP | 2,615,762 | $52,394,000 | 8.42% |
| MPM BioImpact LLC | 918,310 | $18,394,000 | 4.36% |
| BVF INC/IL | 3,444,420 | $68,992,000 | 2.85% |
| Boxer Capital, LLC | 1,900,000 | $38,057,000 | 2.14% |
| Opaleye Management Inc. | 253,200 | $5,072,000 | 2.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 295,136 | $5,912,000 | 2.00% |
| TCG Crossover Management, LLC | 300,000 | $6,009,000 | 1.80% |